Druck Icon

Eckert & Ziegler consolidates therapy business

Berlin, November 20, 2008. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700) will in future be consolidating its activities in the area of radiotherapy within one organization and on December 1, 2008 it will be selling its tumor equipment division and other products for treating cancer, with a combined sales volume of roughly 10 million EUR, to the Belgian company International Brachytherapy S.A. (IBt). The transaction, which will be worth approximately 5 million EUR, will be financed by a long-term vendor loan.

Back in February, Eckert & Ziegler incorporated its Berlin-based implants division into the listed Belgian company and in return for this it received around 40% of the commercial shares in IBt as well as a long-term option to acquire the majority of the shares. By selling off the rest of the therapy activities remaining in Berlin and the commercial business in France to IBt, all of the products for radiation therapists are now combined within one organizational unit.

"Jobs remain unaffected by this measure," explained Dr. Andreas Eckert, founder and CEO of the company. "Essentially the aim of this move is to bring together the Group's therapy activities under one management team once again and to gain greater clout and presence in the market with the enlarged organization. Together with IBt's original implant business, the transaction creates a focused specialist in radio-oncological products with a sales volume of almost 30 million EUR. It will have interesting options for expansion in different directions."

Eckert & Ziegler AG, which in 2008 will achieve sales of approx. 70 million EUR with around 420 employees, is one of the world's largest providers of isotope component technology for radiation therapy, nuclear medicine and industrial applications.

The Board of Directors